# Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

> **NCT02430363** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Medical Research Council** · enrollment: 58 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** MK - 3475
- **BIOLOGICAL:** Suppressor of the PI3K/Akt pathways

## Key facts

- **NCT ID:** NCT02430363
- **Lead sponsor:** Medical Research Council
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2016-01
- **Final completion:** 2018-06
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2016-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430363, "Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02430363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*